Pembrolizumab: all 1,753 studies that test it

Page 12 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsCompletedNCT06307093Phase 1
• A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)TerminatedNCT06295809Phase 2/3
• INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCActive, not recruitingNCT06295731Phase 2/3
• A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLCTerminatedNCT06280196Phase 3
• A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyActive, not recruitingNCT06268613Phase 1
• Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT06242834Phase 2
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06236438Phase 2/3
• BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid TumorsActive, not recruitingNCT06205706Phase 1/2
• Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable MelanomaWithdrawnNCT06190249Phase 1
• Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine CancerActive, not recruitingNCT06180733Phase 2
• Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract CancerActive, not recruitingNCT06178445Phase 2
• Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin LymphomaActive, not recruitingNCT06164275Phase 2
• A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)CompletedNCT06159790Phase 3
• T Cells and Pembrolizumab for Recurrent and Newly Diagnosed GlioblastomaActive, not recruitingNCT06157541Phase 1/2
• Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)Active, not recruitingNCT06155279Phase 2
• A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III MelanomaCompletedNCT06153238Phase 1
• Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung CancerTerminatedNCT06140407Phase 2
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialActive, not recruitingNCT06128863Phase 2
• Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung CancerActive, not recruitingNCT06125197Phase 1
• Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant PembrolizumabWithdrawnNCT06116578Phase 2
• Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal CancerActive, not recruitingNCT06109467Phase 2
• A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid TumorsActive, not recruitingNCT06057038Phase 1
• Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung CancerActive, not recruitingNCT06055465Phase 2
• Study of ALE.C04 in Patients With Head and Neck CancerTerminatedNCT06054477Phase 1/2
• A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)WithdrawnNCT06050954Phase 2
• Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active, not recruitingNCT06049212Phase 1
• A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Active, not recruitingNCT06041802Phase 2
• Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2
• CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT06035744Phase 1
• Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06027268Phase 2
• Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)TerminatedNCT06022757Phase 1/2
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2
• GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerTerminatedNCT05998447Phase 2
• A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid TumorsTerminatedNCT05996445Phase 1
• Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced MelanomaActive, not recruitingNCT05986331Phase 3
• TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT05980598Phase 2
• Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).Active, not recruitingNCT05977907Phase 2
• Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of GlioblastomaWithdrawnNCT05973903Phase 1/2
• A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial CarcinomaActive, not recruitingNCT05929235Phase 1
• A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedNCT05926960Phase 2
• PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin LymphomaActive, not recruitingNCT05922904Phase 2
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive, not recruitingNCT05899049Phase 3
• TEIPP Immunotherapy in Patients With NSCLCCompletedNCT05898763Phase 1/2
• Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLCActive, not recruitingNCT05894889Phase 2
• Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial CancersWithdrawnNCT05894447Phase 1
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent GlioblastomaWithdrawnNCT05879120Phase 2
• A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.Active, not recruitingNCT05878691Phase 1
• Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung CancersTerminatedNCT05860296Phase 1/2
• Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi SarcomaWithdrawnNCT05846724Phase 2
• IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05843448Phase 1
• Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T LymphocytesCompletedNCT05792995Phase 2
• POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingNCT05782361Phase 1
• A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid TumorsCompletedNCT05763004Phase 1
• Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial CancerActive, not recruitingNCT05761951Phase 2
• Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept StudyStatus unknownNCT05761132Phase 2
• A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced MalignanciesCompletedNCT05753722Phase 1
• Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsActive, not recruitingNCT05751187Phase 2
• Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced MalignanciesActive, not recruitingNCT05739006Phase 1
• Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell CarcinomaActive, not recruitingNCT05737199Phase 2
• Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT05721755Phase 3
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3
• IMM60 and Pembrolizumab in Melanoma and NSCLCTerminatedNCT05709821Phase 1/2
• A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)CompletedNCT05708950Phase 1/2
• Neoadjuvant Chemoimmunotherapy in Recurrent GlioblastomaStatus unknownNCT05700955Phase 1
• A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast CancerStatus unknownNCT05681728Phase 2
• A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)Active, not recruitingNCT05675579Phase 2
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1
• CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain MetastasesSuspendedNCT05669352Phase 1/2
• Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT05668949Phase 1/2
• Response to Immunotherapy in MMR-deficient Localized Colon CancerCompletedNCT05662527Phase 2
• A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsActive, not recruitingNCT05653882Phase 1
• SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsActive, not recruitingNCT05642780Phase 2
• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung StudyActive, not recruitingNCT05633602Phase 3
• EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaCompletedNCT05619913Phase 2
• A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid TumorsActive, not recruitingNCT05614102Phase 1
• Electroporation and Immunotherapy in Metastatic Colorectal CancerTerminatedNCT05609656Phase 2
• Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationActive, not recruitingNCT05609578Phase 2
• CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal CancerActive, not recruitingNCT05585814Phase 2
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
• Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
• Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDStatus unknownNCT05578222Phase 2
• A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1
• CISH Inactivated TILs in the Treatment of NSCLCWithdrawnNCT05566223Phase 1/2
• Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Active, not recruitingNCT05563467Phase 2
• BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT05558982Phase 2
• Induction Immunochemotherapy in Stage III-IVa Head and Neck CancerStatus unknownNCT05551767Phase 2
• Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCCompletedNCT05549037Phase 3
• Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal MelanomaWithdrawnNCT05545969Phase 2
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• Pembrolizumab Plus CRT Followed by Surgery in Upper ESCCStatus unknownNCT05541445Phase 1/2
• Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast CancerWithdrawnNCT05539365Phase 2
• A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
• Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaActive, not recruitingNCT05524935Phase 2
• Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)WithdrawnNCT05518032Phase 2
• Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)CompletedNCT05514444Phase 1
• Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric CancerActive, not recruitingNCT05508737Phase 1/2

← Pembrolizumab overview